HuGE Literature Finder
Records
1
-
30
| Concurrent TP53 mutations predict a poor prognosis of EGFR-mutant NSCLCs treated with TKIs: An updated systematic review and meta-analysis. Oncology letters 2022 Nov 24 (5): 384. Lan Bo, Zhao Na, Du Kang, Leng Baola |
| Computed tomography-guided lung biopsy for molecular tests: a meta-analysis. Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery 2022 Jun 19 (2): 96-101. Zhang Jian-Hua, Xia Feng-Fei, Yang Xiao-Shan, Li |
| Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-Analysis. Journal of clinical medicine 2022 Jun 11 (12): . Lee Tai-Huang, Chen Hsiao-Ling, Chang Hsiu-Mei, Wu Chiou-Mei, Wu Kuan-Li, Kuo Chia-Yu, Wei Po-Ju, Chen Chin-Ling, Liu Hui-Lin, Hung Jen-Yu, Yang Chih-Jen, Chong Inn-W |
| Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis. ESMO open 2022 Jun 7 (3): 100507. Dafni U, Soo R A, Peters S, Tsourti Z, Zygoura P, Vervita K, Han J-Y, De Castro J, Coate L, Früh M, Hashemi S M S, Nadal E, Carcereny E, Sala M A, Bernabé R, Provencio M, Cuffe S, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R |
| Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer. Targeted oncology 2022 Jun . Tan Elaine S, Fan Wenyi, Knepper Todd C, Schell Michael J, Sahin Ibrahim H, Fleming Jason B, Xie H |
| Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis. Targeted oncology 2022 Feb . Van Sanden Suzy, Murton Molly, Bobrowska Anna, Rahhali Nora, Sermon Jan, Rodrigues Bernardo, Goff-Leggett Danielle, Chouaid Christos, Sebastian Martin, Greystoke Alasta |
| Prognostic biomarkers of malignant patients with pleural effusion: a systematic review and meta-analysis. Cancer cell international 2022 Feb 22 (1): 99. Peng Peng, Yang Yuan, Du Juan, Zhai Kan, Shi Huan-Zho |
| Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2022 Jan 166 9-16. Huang Le-Tian, Zhang Shu-Ling, Han Cheng-Bo, Ma Jie-T |
| Clinical and CT patterns to predict EGFR mutation in patients with non-small cell lung cancer: A systematic literature review and meta-analysis. European journal of radiology open 2022 2 9 100400. Ortiz Andrés Felipe Herrera, Camacho Tatiana Cadavid, Vásquez Andrés Francisco, Del Castillo Herazo Valeria, Neira Juan Guillermo Arámbula, Yepes María Mónica, Camacho Eduard Cadav |
| Efficacy of adjuvant EGFR inhibitors and impact of clinical factors in resected EGFR-mutated non-small-cell lung cancer: a meta-analysis. Future oncology (London, England) 2022 2 18 (9): 1159-1169. Li Meichen, Hou Xue, Lin Suxia, Zheng Lie, Liang Jianzhong, Chen Jing, Wang Na, Zhang Baishen, Chen Lik |
| Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis. Frontiers in oncology 2022 12 863666. Yi Xiao-Fang, Song Jun, Gao Ruo-Lin, Sun Li, Wu Zhi-Xuan, Zhang Shu-Ling, Huang Le-Tian, Ma Jie-Tao, Han Cheng- |
| First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis. Therapeutic advances in chronic disease 2022 10 13 20406223221125706. Chen Chongxiang, Zhang Chunning, Lin Huaming, Liu Qianyin, Wu Limian, Zhou Chengzhi, Zhang Jiex |
| Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis. Molecular diagnosis & therapy 2021 Nov . Melosky Barbara, Kambartel Kato, Häntschel Maik, Bennetts Margherita, Nickens Dana J, Brinkmann Julia, Kayser Antonin, Moran Michael, Cappuzzo Federi |
| Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis. European review for medical and pharmacological sciences 2021 Oct 25 (20): 6232-6244. Lee H J, Jeong G H, Li H, Kim M S, Kim J S, Park S J, Han Y J, Lee K H, Kronbichler A, Hong S H, Ghayda R A, Luchini C, Nottegar A, Koyanagi A, Smith L, Jacob L, Dragioti E, Radua J, Cargnin S, Terrazzino S, Thompson T, Yon D K, Lee S W, Yang J M, Wasuwanich P, Shin J I, Gamerith |
| Systematic Review and Meta-analysis of the Most Common Genetic Mutations in Esophageal Squamous Cell Carcinoma. Journal of gastrointestinal cancer 2021 Oct . Naseri Amirreza, Salehi-Pourmehr Hanieh, Majidazar Reza, Seraji Parya, Rezazadeh-Gavgani Erfan, Zehtabi Mojtaba, Kiani-Kezbin Hamed, Salehnia Fatemeh, Hassannezhad Sina, Hajikamanj Arash, Raeisi Morta |
| EGFR mutation status in non-small cell lung cancer receiving PD-1/PD-L1 inhibitors and its correlation with PD-L1 expression: a meta-analysis. Cancer immunology, immunotherapy : CII 2021 Sep . Yang Huimin, Zhu Jinxiu, Xiao Rendong, Liu Yuhang, Yu Fanglin, Cai Lin, Qiu Minglian, He F |
| EGFR-plasma mutations in prognosis for non-small cell lung cancer treated with EGFR TKIs: A meta-analysis. Cancer reports (Hoboken, N.J.) 2021 Aug e1544. Phan Thang Thanh, Tran Vinh Thanh, Tran Bich-Thu, Ho Toan Trong, Pho Suong Phuoc, Le Anh Tuan, Le Vu Thuong, Nguyen Hang Thuy, Nguyen Son Truo |
| Driver and novel genes correlated with metastasis of non-small cell lung cancer: A comprehensive analysis. Pathology, research and practice 2021 Jul 224 153551. Wu Yongfeng, Ni Heng, Yang Dexin, Niu Yuequn, Chen Kelie, Xu Jinming, Wang Fang, Tang Song, Shi Yu, Zhang Honghe, Hu Jian, Xia Dajing, Wu Yih |
| EGFR tyrosine kinase inhibitors alone or in combination with chemotherapy for non-small-cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials. Journal of cancer research and therapeutics 2021 Jul 17 (3): 664-670. Zhu Cui-Min, Lian Xiang-Yao, Zhang Hong-Yan, Bai Lu, Yun Wen-Jing, Zhao Ru-Han, Li Qing-Sh |
| Prevalence of Targetable Mutations in Black Patients With Lung Cancer: A Systematic Review and Meta-Analysis. JCO oncology practice 2021 May 17 (5): e629-e636. Costa Philippos A, Saul Eduardo E, Paul Yonette, Iyer Sunil, da Silva Laercio Lopes, Tamariz Leonardo, Lopes Gilber |
| Efficacy of immune checkpoint inhibitors in the treatment of non-small cell lung cancer patients with different genes mutation: A meta-analysis. Medicine 2021 Mar 100 (10): e19713. Zhang Rui, Zhu Jing, Liu Ying, Xin Ying, Wang Ying, Niu Kai, Wei Huafa |
| Systemic Inflammatory Markers of Survival in Epidermal Growth Factor-Mutated Non-Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis. Clinical lung cancer 2021 Jan . Chan Sze Wah Samuel, Smith Elliot, Aggarwal Reenika, Balaratnam Karmugi, Chen RuiQi, Hueniken Katrina, Fazelzad Rouhi, Weiss Jessica, Jiang Shirley, Shepherd Frances A, Bradbury Penelope A, Sacher Adrian G, Leighl Natasha B, Xu Wei, Brown M Catherine, Eng Lawson, Liu Geoffr |
| Adjuvant EGFR-TKIs for Patients With Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis of 1,283 Patients. Frontiers in oncology 2021 11 629394. Chen Rui-Lian, Sun Ling-Ling, Cao Yang, Chen Han-Rui, Zhou Jing-Xu, Gu Chu-Ying, Zhang Ying, Wang Si-Yu, Hou Wei, Lin Li-Z |
| Current Evidence of the Efficacy and Safety of Neoadjuvant EGFR-TKIs for Patients With Non-small Cell Lung Cancer. Frontiers in oncology 2021 11 608608. Shi Xiaoshun, Dong Xiaoying, Zhai Jianxue, Liu Xiguang, Lu Di, Ni Zhen, Wu Hua, Cai Kaic |
| Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence. Journal of oncology 2021 12 2021 8736288. Zhang Lemeng, Luo Yongzhong, Chen Jianhua, Cheng Tianli, Yang Hua, Pan Changqie, Li Haitao, Jiang Zh |
| Plasma ctDNA RAS status selects patients for anti-EGFR treatment rechallenge in metastatic colorectal cancer: a meta-analysis. Experimental oncology 2021 09 43 (3): 252-256. Vlachou M S, Mauri D, Zarkavelis G, Ntellas P, Tagkas C, Gkoura S, Pentheroudakis |
| Prognostic Value of BIM Deletion in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs: A Meta-Analysis. BioMed research international 2021 2021 3621828. Lv Fangfang, Sun Liang, Yang Qiuping, Pan Zheng, Zhang Yuh |
The role of circulating galectin-1 in type 2 diabetes and chronic kidney disease: evidence from cross-sectional, longitudinal and Mendelian randomisation analyses.
Diabetologia 2021 11 65 (1): 128-139. Drake Isabel, Fryk Emanuel, Strindberg Lena, Lundqvist Annika, Rosengren Anders H, Groop Leif, Ahlqvist Emma, Borén Jan, Orho-Melander Marju, Jansson Per-Ande |
| The role of EGFR-TKIs as adjuvant therapy in EGFR mutation-positive early-stage NSCLC: A meta-analysis. Thoracic cancer 2021 04 12 (7): 1084-1095. Lin Chutong, Hu Fengling, Chu Hongling, Ren Peng, Ma Shanwu, Wang Jingdi, Bai Jie, Han Xuan, Ma Shaoh |
| KRAS and BRAF mutations in Iranian colorectal cancer patients: A systematic review and meta-analysis. Caspian journal of internal medicine 2020 11 (4): 355-369. Yari Abolfazl, Afzali Asiyeh, Aalipour Mostafa, Nakheai Mehran, Zahedi Mohammad Jav |
- Page last reviewed:Feb 1, 2023
- Page last updated:Feb 03, 2023
- Content source: